Methods

PASS Study Recruitment
The PASS study recruited children in two stages, firstly for a discovery cohort, and subsequently for a validation cohort. The validation cohort was specifically recruited for this purpose. There were no differences in the protocol between the two phases of recruitment.
Consent process
Participants and families were identified by hospital paediatricians. Information was given to the family and consent obtained from the parent/guardian (or participant if ≥16 years) after at least 24 hours consideration. Assent was also sought from older participants (age 12-15 years, judged on a case by case basis). Participants judged able to give assent, but who declined, were excluded.
Design of the LDSST
We based the sampling regimen for LDSST on that developed by Paton et al 1 .
In that study, LDSST consisted of a dose of 500ng/1.73m 2 and sampling at 0, 15, 20, 25, 30 and 35 minutes. Raw data from that audit 1 were reviewed and measurements from four of the six time points (0, 15, 25, 35 minutes) were able to consistently distinguish between normal and abnormal responses (18) . A minority of patients included in PASS were recruited having already undergone a LDSST within the last 2 years using the local protocol at the recruiting institution.
Statistical analysis
For the preliminary study of demographic and clinical factors, analyses were undertaken in SAS v.9.2 (Cary, NC, US). For times when multiple comparisons were carried out, a Bonferroni correction was used and a significant p-value assumed to be <0. 005 
Calculating corticosteroid cumulative dose
Doses of corticosteroid taken by participants were expressed as micrograms/day of beclomethasone diproprionate equivalent 3 . Dose ratios of 1:1 (Beclomethasone Diproprionate CFC, Clenil Modulite, Budesonide) 4 , 2:1 (Fluticasone, Mometasone, Qvar) 4 and 1:3.9 (Prednisolone) were used 5 .
Patient's corticosteroid cumulative dose over the previous six months was then calculated in three different ways:
1)
Mean daily inhaled/intranasal corticosteroid cumulative dose in six months prior to LDSST (cumulative dose of inhaled and intranasal corticosteroid medications, regardless of rescue therapies and excluding those on regular oral corticosteroids, expressed as a mean daily dose of beclomethasone diproprionate equivalent).
2) Number of courses of rescue oral corticosteroids required to treat exacerbations of asthma in the preceding 6 months before the LDSST.
3)
Mean daily total corticosteroid cumulative dose in six months prior to LDSST (cumulative dose of inhaled, intranasal and regular oral corticosteroid medications as well as rescue courses, assuming a course of rescue corticosteroids is a three day course of oral prednisolone, dosed at 2 mg/kg per day (to a maximum dose of 40 mg), expressed as a mean daily dose of beclomethasone diproprionate equivalent).
All dose calculations assume 100% concordance and bioavailability (regardless of route of administration). Topical corticosteroid preparations applied to the skin were not included in the total corticosteroid dose calculations due to uncertainty about the dose received due to variations in both the surface area of the body affected and quantity of cream applied.
Adherence with corticosteroids in asthma has previously been assessed using prescription fill-refill data 6 . Repeat prescription data for the 6 months prior to the date of the LDSST were supplied by general practitioners (GP) of patients recruited from a single centre. Using the strength of inhaler prescribed, number of doses per inhaler (from manufacturers SPC) and prescribed dose, the minimum number of refills required by the patient in the 6 month period was calculated and compared with the actual number of refills collected. For the statistically significant relationship(s), the effect of variation in the population adherence was calculated. 
PASIC STUDY
Exclusion Criteria:
History of anaphylaxis to synacthen
History of adrenal disease
On long term oral prednisolone or hydrocortisone or taken oral corticosteroid in the last 4 weeks
Patients taking Nasal steroids Participating in another study.
Patients with a significant disease other than COPD; a significant disease is defined as a co-morbidity (respiratory and non-respiratory) which, in the opinion of the investigator, may i) Put the patient at risk because of participation in the study,
ii)
Influence the results of the study, or iii) Cause concern regarding the patient's ability to participate in the study Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits.
Pregnancy
Recruitment sites and recruitment leads
The following UK recruiting centres and Principal Investigators were involved in the PASS study: 
LDSST procedure and interpretation
For all prospectively recruited patients (PASS and all PASIC patients), the LDSST procedure was undertaken as follows: all tests were commenced before 11:00am and as close to 7:00am as possible. Participants were not fasted, but any corticosteroid medicine was withheld on the morning of the LDSST until test completion. For patients in the PASS cohort treated with alternate day oral corticosteroid, the LDSST was performed on the day a dose was due to be given, withholding it until completion of the LDSST. For retrospectively recruited patients (subset of PASS patients only), the LDSST was undertaken using the clinical protocol from the recruiting hospital. The dose of Synacthen used, timing of the LDSST and timing of sample collection were all recorded.
Identification of the correct threshold for diagnosis of adrenal suppression in children is difficult, as there are limited normative data. For paediatric populations, a peak cortisol of 350nmol/L has been shown to be the most sensitive and specific at determining adrenal insufficiency 8 , although a threshold of 500nmol/L is still widely used clinically. For adults, 500nmol/L is the accepted threshold. In a detailed review of symptomatic cases of adrenal insufficiency during ICS use in childhood asthma 8 , there were no published cases in patients with peak cortisol concentrations >350nmol/L in either standard dose or low dose tests. For this study, we have therefore used <350nmol/L as our primary outcome for children within the PASS study populations, and <500nmol/L for the adults in the PASIC study.
All of the NHS trusts participating in this study analysed their own cortisol samples. All NHS laboratories subscribe to an external quality assurance (EQA) scheme, through the UK National Quality Assurance Scheme (UKNEQAS), to ensure consistency and robust analytical quality.
Sample size calculation
The target sample size for the primary analysis cohort was 500. To arrive at this estimate we considered two possible scenarios: (a) an odds ratio (OR) of 3 for association between a rare variant (minor allele frequency=5%) and the primary outcome; (b) an OR of 2 for association between a common variant (minor allele frequency=20%) and the primary outcome. A liberal type 1 error rate of 5% was assumed on the basis that validation cohorts would also be analysed to help eliminate false positives arising from the initial analyses. Assuming first of all prevalence of impaired adrenal response in children with asthma using inhaled steroid to be 17% (based on a the lower end of the range of previously published rates of adrenal suppression 2 ) the power for scenario a) was calculated as 77% and the power for scenario b) was calculated as 75%. If the prevalence was 40%
(the upper end of the range of published estimates 2 ), the power increased to 91% for both scenarios. A prevalence of 20% would ensure power of at least 80% in both scenarios.
DNA Storage and Extraction
For all cohorts, patient samples for DNA were collected as whole blood (EDTA) or salivary samples (2ml saliva). DNA collection and extraction for saliva samples has been described previously 11 . EDTA blood samples were stored at -20°C and, following defrosting, genomic DNA was extracted using the Chemagen whole-blood DNA extraction kit on the Chemagic Magnetic Separation Module I according to the manufacturer's protocol (PerkinElmer chemagen Technologie GmbH, Baesweiler, Germany; www.chemagen.com).
Genotyping quality control (QC) and Imputation
Patients within the primary analysis cohort were excluded from association analyses if any of the following criteria were met: a) gender as determined by the "Sex Check" function within PLINK Hardy-Weinberg Equilibrium (HWE), taken as p<0.0001 or c) genotyping success rate was <95%. All QC analysis was undertaken using PLINK v1.07 12 unless otherwise stated. The same SNP quality control criteria were also applied to the WTCCC and both of the validation cohorts.
The overlapping SNPs in the primary analysis cohort genotypes with WTCCC dataset were merged.
Before merging, any A/T and G/C SNPs were removed to avoid strand flip issues. The merged dataset was then subject to SNP phasing using SHAPEIT 14 and imputation using IMPUTE2 
Statistical Analysis
In the primary analysis cohort, to test for association, regression models assuming an additive genetic model were fitted in SNPtest using each SNP as a covariate in an independent model. To adjust for population substructure we included up to five principal components as covariates in this genome-wide analysis, subject to the principal components being significantly associated with the outcome univariately (p<0.05). If no principal components were significantly associated with the outcome, the first two principal components were included as covariates in genome-wide analysis.
Previously in Hawcutt et al. (2015) 2 , the cumulative dose in the past 6 months was identified as significantly associated with impaired peak cortisol (see supplementary data section). However, due to the inclusion of WTCCC in the control group, cumulative dose could not be adjusted for in the genome-wide analysis of binary outcomes.
Secondary analyses were also undertaken within the primary analysis cohort to test for association with peak cortisol levels and baseline cortisol levels, both as continuous phenotypes. Baseline cortisol level data were logarithmically transformed to achieve normality. Tests for association between each SNP in turn and phenotype were undertaken by fitting linear regression models in SNPtest, again with two principle components included as covariates. A covariate to adjust for total corticosteroid dose and age was also included in the regression models for peak and baseline phenotypes respectively. These covariates were chosen based on our previous findings 2 . In all analyses, as an additive genetic model was assumed, all odds ratios reflect the comparison between heterozygotes versus wild-type homozygotes.
Selection of genes for validation
Any SNPs located within genes (including all promoter and intronic regions) identified in the primary analysis cohort, with a p value <1x10 -6 for association with any of the phenotypes were considered for validation. Commonly, the threshold of 1x10 -5 is used in genome-wide analysis as a threshold of "nominal significance", but for this study we considered the lower threshold of 1x10 -6 to reduce the risk of identifying false positive results whilst taking into consideration the small size of the PASS cohort.
If multiple SNPs achieved significance, then the decision on which to undertake validation was based on the presence of genotyped SNPs, the credibility of the LocusZoom plot (i.e. a reasonable LD structure of proportionality between ascending r 2 values and descending p-values), and supporting evidence of biological plausibility.
As the use of WTCCC controls can lead to false positive associations due to assuming a >350nmol/L corticosteroid level or >500nmol/L corticosteroid level response when exposed to the PASS study conditions, further analysis was conducted on SNPs (and their regions) recommended for validation using only the PASS dataset without the WTCCC controls. In this further analysis, we adjusted for significant clinical covariates (cumulative dose) and any applicable interaction effects between clinical covariates and genetic loci (if significant at the 5% level).
Genotyping of validation samples was undertaken using Taqman allelic discrimination assay C___1951874_10 (Thermo Fisher Scientific, Paisley, UK) according to the manufacturer's protocol.
All individuals were genotyped in duplicate and an absolute requirement for concurrence between the 2 samples, as well as a genotyping call rate of >95% and a Hardy Weinberg p-value of >0.0001
were applied, for quality control. Statistical analyses of SNPs selected for validation were conducted in R 17 repeating the same methodology as that used for genome-wide analysis, i.e. logistic regression with binary phenotypes and linear regression with continuous phenotypes with adjustment for the same covariates as the genome-wide analysis.
Comparison with the CORNET consortium data
The association between rs591118 and morning plasma cortisol was investigated in 12 studies that participated in the discovery and replication stages of the CORtisol NETwork (CORNET) consortium genome-wide association meta-analysis 18 
Pathway Analysis
We used MAGENTA 20 to scrutinise the results from all phenotypes to identify any enrichment of functional and biological pathways. SNPs were annotated to genes if they fell within a 5kb boundary surrounding a gene (including all promotor and intronic regions) 21 . The pathways and ontology terms used in MAGENTA are from Biocarta, KEGG, Ingenuity, Panther, Reactome and Gene Ontology (GO) databases. We refined the databases down to the pathway and ontology terms that included the genes that had been identified through annotation of the SNPs selected for validation.
Pathways were not limited to gene set size. A nominal p-value for Gene Set Enrichment Analysis (GSEA) was calculated through permutation via random resampling of 10,000 gene sets of identical size. Both MAGENTA thresholds for gene-level association signals were utilised (75 th and 95 th percentile), to ensure that weaker gene-level association signals could still be investigated. The FDR threshold of 5% was chosen across all pathway analyses to indicate a significant pathway.
The Ingenuity® Pathway Analysis software (IPA®, QIAGEN Redwood City), which is powered by manually curated literature within the Ingenuity Knowledge Base, was utilised to explore the known gene networks and regulatory cascades that lead to or from our identified gene.
Results
Review of Publications looking for biological plausibility
Publications for PDGFD and TRPA1 were reviewed to examine possible biological plausibility. There were no relevant publications noted for six of the eight genes. TRPA1 has been associated with Familial Episodic Pain Syndrome
22
, and TRPA1 expression (after painful stimuli) has been linked to increased HPA axis responses in mice 23 . Pain is well recognised as a stimulus to the HPA axis, as part of its normal function. In relation to PDGFD, PDGF receptors are required in the development of steroid-producing cells in multiple organs, including the testis, ovary, and adrenal cortex 24 . In addition, expression of PDGFD has been negatively correlated with cortisol secretion in adrenocortical adenomas 25 . This was the only publication from any of the genes related to altered cortisol secretion.
Pathway Analysis
Sixteen pathways were included in a pathway analysis that contained the PDGFD gene. There were two pathways identified that were associated with a FDR corrected p value <0.05 (see supplementary data). These were Focal Adhesion and Regulation of Actin Cytoskeleton, both from the KEGG database. We also used IPA® to evaluate the biological interactions and pathways known to encompass PDGFD. Within the canonical PDGF signalling pathway involving PDGFD, several cytoplasmic signalling proteins are recruited, leading to the activation of a number of key signalling cascades including the mobilization of cytosolic calcium and mitogen activated protein kinase (MAPK) pathway.
Number needed to test full methodology
For children with asthma prescribed ICS, we first calculate the Number Needed to Test (NNT) in the PASS replication cohort, as the effect size can be considered unbiased. Considering the rs591118 genotype within the PASS validation cohort, using the <350nmol/L definition of adrenal suppression, the frequency of adrenal suppression in the wild-type homozygous (GG) group is 0.029 (2.9 per 100);
heterozygous (AG) group is 0.097 (9.7 per 100); mutant-type homozygous group (AA) is 0. 
